ストックスクリーナーアプリを入手
1.32
1.54%
0.02
アフターアワーズ：
1.26
-0.06
-4.55%
Galectin Therapeutics Inc (GALT) 最新ニュース
Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister
Portal Hypertension Market Growth Projections 2023-2032: - openPR.com
MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter
9 Short Squeeze Stocks That Could Take Off - US News Money
Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail
Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail
CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail
MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter
HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World
HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
SPY ETF News, 4/3/2025 - The Globe and Mail
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):